RTQ1 Stock Overview
Develops cancer drugs and in vitro diagnostics in the United Kingdom, France, North America, South Korea, rest of Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Risk Analysis
Avacta Group Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.52 |
| 52 Week High | UK£1.59 |
| 52 Week Low | UK£0.41 |
| Beta | 1.18 |
| 11 Month Change | -17.46% |
| 3 Month Change | -38.46% |
| 1 Year Change | -66.45% |
| 33 Year Change | -62.86% |
| 5 Year Change | n/a |
| Change since IPO | -66.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| RTQ1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 5.3% | -0.2% | 0.8% |
| 1Y | -66.5% | -16.9% | 9.1% |
Return vs Industry: RTQ1 underperformed the German Biotechs industry which returned -16.9% over the past year.
Return vs Market: RTQ1 underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| RTQ1 volatility | |
|---|---|
| RTQ1 Average Weekly Movement | 15.1% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: RTQ1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: RTQ1's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 154 | Chris Coughlin | www.avacta.com |
Avacta Group Plc develops cancer drugs and in vitro diagnostics in the United Kingdom, France, North America, South Korea, rest of Europe, and internationally. The company operates through Diagnostics and Therapeutics segments. It provides its proprietary Affimer and pre|CISION technology platforms, which is used to deliver a portfolio of differentiated th therapeutic and diagnostic products that addresses various markets.
Avacta Group Plc Fundamentals Summary
| RTQ1 fundamental statistics | |
|---|---|
| Market cap | €210.52m |
| Earnings (TTM) | -€31.03m |
| Revenue (TTM) | €27.11m |
7.8x
P/S Ratio-6.8x
P/E RatioIs RTQ1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RTQ1 income statement (TTM) | |
|---|---|
| Revenue | UK£22.62m |
| Cost of Revenue | UK£13.10m |
| Gross Profit | UK£9.52m |
| Other Expenses | UK£35.40m |
| Earnings | -UK£25.89m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.071 |
| Gross Margin | 42.08% |
| Net Profit Margin | -114.45% |
| Debt/Equity Ratio | 49.8% |
How did RTQ1 perform over the long term?
See historical performance and comparison